INVESTOR PRESENTATION Dr Bill Ketelbey CEO March 2017
DISCLAIMER This presentation has been prepared by Actinogen Medical Limited. (“ Actinogen ” or the “Company”) based on information available to it as at the date of this presentation. The information in this presentation is provided in summary form and does not contain all information necessary to make an investment decision. This presentation does not constitute an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any security in Actinogen, nor does it constitute financial product advice or take into account any individual’s investment objectives, taxation situation, financial situation or needs. An investor must not act on the basis of any matter contained in this presentation but must make its own assessment of Actinogen and conduct its own investigations. Before making an investment decision, investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Actinogen is not licensed to provide financial product advice in respect of its securities or any other financial products. Cooling off rights do not apply to the acquisition of Actinogen securities. Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Actinogen its officers, directors, employees and agents, nor any other person, accepts any responsibility and liability for the content of this presentation including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of or reliance on any of the information contained in this presentation or otherwise arising in connection with it. The information presented in this presentation is subject to change without notice and Actinogen does not have any responsibility or obligation to inform you of any matter arising or coming to their notice, after the date of this presentation, which may affect any matter referred to in this presentation. The distribution of this presentation may be restricted by law and you should observe any such restrictions. This presentation contains certain forward looking statements that are based on the Company’s management’s beliefs, assumptions and expectations and on information currently available to management. Such forward looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results or performance of Actinogen to be materially different from the results or performance expressed or implied by such forward looking statements. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the political and economic environment in which Actinogen will operate in the future, which are subject to change without notice. Past performance is not necessarily a guide to future performance and no representation or warranty is made as to the likelihood of achievement or reasonableness of any forward looking statements or other forecast. To the full extent permitted by law, Actinogen and its directors, officers, employees, advisers, agents and intermediaries disclaim any obligation or undertaking to release any updates or revisions to information to reflect any change in any of the information contained in this presentation (including, but not limited to, any assumptions or expectations set out in the presentation). 2
OVERVIEW 3
A A lzheimer’s disease is the leading cause of death in the UK and Europe and the second leading DEVASTATING cause of death in Australia. DISEASE Of the top-ten leading fatal illnesses, it remains the only one that cannot be prevented, treated or cured. Drugs available to treat Alzheimer's disease provide limited benefit. 4
CORPORATE OVERVIEW Actinogen Medical (ASX:ACW) is focused on an innovative approach for treating Alzheimer's S T O C K M E T R I C S * disease and cognitive impairment in chronic neurodegenerative diseases, through the inhibition of cortisol production. • The Company is developing Xanamem™, a novel drug for treating Alzheimer’s disease, which has been specifically designed to block the production of cortisol in the brain. • The inhibition of cortisol is a new approach in treating A S X C O D E A C W Alzheimer’s disease. Market Capitalisation $36.4m • There is a growing body of research reinforcing the strong Enterprise Value $30.6m association between excess cortisol and the development and progression of Alzheimer’s disease. 52-week High/Low $0.04-$0.10 • Xanamem™ has the potential to treat multiple other Top 20 Shareholdings 55% conditions, including diabetes cognitive impairment and PTSD. * Data as at 24 March 2017. 5
A SIMPLE BUT COMPELLING STORY 1 2 3 4 5 Xanamem™ - a Independent research Human trial of cortisol Xanamem ™ Phase I human trials novel therapy for shows a strong inhibition in the brain demonstrated a confirm that Xanamem ™ Alzheimer's disease that association between demonstrates cognitive significant improvement successfully crosses the suppresses cortisol excess cortisol in the improvement in the in cognition in a mouse blood-brain barrier and is (stress hormone) brain and Alzheimer’s elderly. (Sundeep at al 2004) model of AD after only 28 safe for use in humans. (Walker et al 2017) production in the brain. disease. days treatment, which continued out to 41 weeks. (Sooy et al 2015) 6
BOARD OF DIRECTORS DR GEOFF BROOKE CHAIRMAN Dr Brooke is a clinically trained physician turned venture capitalist with over 30 years' experience in the healthcare investment industry. He was the founder and managing director of two venture capital firms, Medvest Inc and GBS Venture Partners. GBS is viewed as one of the Asia Pacific region's premier healthcare venture investors. Dr Brooke has been a major investor, chairman or director of companies in the healthcare sector with a combined realised value of $1.5 billion. Dr Brooke's expertise includes assisting high growth technology-based companies in areas such as development strategy, clinical trial design, fund raising, management structuring and investment exits. Dr Brooke is a medical graduate of the University of Melbourne and has an MBA from IMEDE (now IMD), Lausanne Switzerland. DR BILL KETELBEY CEO & MANAGING DIRECTOR Dr Ketelbey has 30 years' experience in the healthcare and pharmaceutical industry, including senior medical and management roles in the Asia Pacific Region with global pharmaceutical company Pfizer. Dr Ketelbey led the local clinical development, and was involved in the commercialisation, of Aricept™ (donepezil), the market - leading Alzheimer’s d isease therapy. More recently, he was involved in developing another therapy directed at clearing the amyloid plaques that are a feature of disease progression in Alzheimer’s. Dr Ketelbey is a medical graduate from the University of the Witwatersrand, South Africa and a Fellow of the Faculty of Pharmaceutical Physicians from the Royal College of Physicians in the United Kingdom. He also has an MBA from Macquarie Graduate School of Management, Australia, and is a Graduate of the Australian Institute of Company Directors. DR JASON LOVERIDGE NON-EXECUTIVE DIRECTOR Dr Loveridge has been working in the biomedical technology industry for over 20 years and has extensive experience in developing clinical stage biotechnology companies. As a venture investor with JAFCO Nomura, Dr Loveridge participated and invested in the start-up of over 24 companies in Europe, the United States and Israel. Since 2005, he has been directly involved in senior management of a number of small innovative companies in the biomedical field, specifically in refinancing and product commercialisation. In addition to Actinogen Medical, Dr Loveridge is also a Non-Executive Director of Resonance Health (ASX: RHT) and CEO of German based biopharmaceutical company 4SC AG. DR ANTON UVAROV NON-EXECUTIVE DIRECTOR Dr Uvarov has significant experience as an equity analyst in the healthcare industry with a focus on biotechnology, both domestically and internationally. Prior to moving to Australia, he was with Citigroup Global Markets where he spent two years as a member of New York based biotechnology team that has been continuously ranked in the top four (in Biotechnology) in the All-America Institutional Investor survey. Dr Uvarov’s scientific expertise and company knowledge spreads across a variety of therapeutic areas and spectrum of market capitalizations and he has a particular interest in early stage biotechnology companies. Dr Uvarov holds a PhD degree in Biochemistry and Medical Genetics from the University of Manitoba, Canada and an MBA degree from the University of Calgary, Canada. 7
Recommend
More recommend
